Incyte Corporation-Product Pipeline Review-2015

Incyte Corporation-Product Pipeline Review-2015

  • Products Id :- GMDHC06917CDB
  • |
  • Pages: 69
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Incyte Corporation-Product Pipeline Review-2015


Global Markets Direct's, 'Incyte Corporation-Product Pipeline Review-2015', provides an overview of the Incyte Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Incyte Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Incyte Corporation including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Incyte Corporation's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Incyte Corporation's pipeline products

Reasons To Buy

Evaluate Incyte Corporation's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Incyte Corporation in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Incyte Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Incyte Corporation and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Incyte Corporation

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Incyte Corporation and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Incyte Corporation Snapshot 6

Incyte Corporation Overview 6

Key Information 6

Key Facts 6

Incyte Corporation-Research and Development Overview 7

Key Therapeutic Areas 7

Incyte Corporation-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Pipeline Products-Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products-Out-Licensed Products 15

Out-Licensed Products/Combination Treatment Modalities 16

Incyte Corporation-Pipeline Products Glance 17

Incyte Corporation-Late Stage Pipeline Products 17

Pre-Registration Products/Combination Treatment Modalities 17

Phase III Products/Combination Treatment Modalities 18

Incyte Corporation-Clinical Stage Pipeline Products 19

Phase II Products/Combination Treatment Modalities 19

Phase I Products/Combination Treatment Modalities 20

Incyte Corporation-Early Stage Pipeline Products 21

Preclinical Products/Combination Treatment Modalities 21

Discovery Products/Combination Treatment Modalities 22

Incyte Corporation-Drug Profiles 23

ruxolitinib phosphate 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

epacadostat 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

INCB-39110 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

INCB-050465 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

INCB-052793 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

INCB-40093 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

INCB-54828 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

INCB-54329 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Monoclonal Antibodies to Agonize GITR for Cancer 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Monoclonal Antibody to Agonize OX-40 for Cancer 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Monoclonal Antibody to Antagonize TIM-3 for Cancer 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Monoclonal Antibody to Inhibit LAG-3 for Cancer 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Small Molecule for Acute Leukemia 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Small Molecules for Chronic Inflammation 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Incyte Corporation-Pipeline Analysis 45

Incyte Corporation-Pipeline Products by Target 45

Incyte Corporation-Pipeline Products by Route of Administration 47

Incyte Corporation-Pipeline Products by Molecule Type 48

Incyte Corporation-Pipeline Products by Mechanism of Action 49

Incyte Corporation-Recent Pipeline Updates 50

Incyte Corporation-Dormant Projects 62

Incyte Corporation-Discontinued Pipeline Products 63

Discontinued Pipeline Product Profiles 63

aderbasib 63

INCB-047986 63

Incyte Corporation-Company Statement 64

Incyte Corporation-Locations And Subsidiaries 67

Head Office 67

Other Locations & Subsidiaries 67

Appendix 68

Methodology 68

Coverage 68

Secondary Research 68

Primary Research 68

Expert Panel Validation 68

Contact Us 68

Disclaimer 69

List of Tables

Incyte Corporation, Key Information 6

Incyte Corporation, Key Facts 6

Incyte Corporation-Pipeline by Indication, 2015 8

Incyte Corporation-Pipeline by Stage of Development, 2015 11

Incyte Corporation-Monotherapy Products in Pipeline, 2015 12

Incyte Corporation-Partnered Products in Pipeline, 2015 13

Incyte Corporation-Partnered Products/ Combination Treatment Modalities, 2015 14

Incyte Corporation-Out-Licensed Products in Pipeline, 2015 15

Incyte Corporation-Out-Licensed Products/ Combination Treatment Modalities, 2015 16

Incyte Corporation-Pre-Registration, 2015 17

Incyte Corporation-Phase III, 2015 18

Incyte Corporation-Phase II, 2015 19

Incyte Corporation-Phase I, 2015 20

Incyte Corporation-Preclinical, 2015 21

Incyte Corporation-Discovery, 2015 22

Incyte Corporation-Pipeline by Target, 2015 46

Incyte Corporation-Pipeline by Route of Administration, 2015 47

Incyte Corporation-Pipeline by Molecule Type, 2015 48

Incyte Corporation-Pipeline Products by Mechanism of Action, 2015 49

Incyte Corporation-Recent Pipeline Updates, 2015 50

Incyte Corporation-Dormant Developmental Projects,2015 62

Incyte Corporation-Discontinued Pipeline Products, 2015 63

Incyte Corporation, Subsidiaries 67

List of Figures

Incyte Corporation-Pipeline by Top 10 Indication, 2015 8

Incyte Corporation-Pipeline by Stage of Development, 2015 11

Incyte Corporation-Monotherapy Products in Pipeline, 2015 12

Incyte Corporation-Partnered Products in Pipeline, 2015 13

Incyte Corporation-Out-Licensed Products in Pipeline, 2015 15

Incyte Corporation-Pipeline by Top 10 Target, 2015 45

Incyte Corporation-Pipeline by Top 10 Route of Administration, 2015 47

Incyte Corporation-Pipeline by Top 10 Molecule Type, 2015 48

Incyte Corporation-Pipeline Products by Top 10 Mechanism of Action, 2015 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Incyte Corporation; Incyte Corporation - Key Therapeutics; Incyte Corporation - Pipeline Overview and Promising Molecules; Incyte Corporation - News; Incyte Corporation - Latest Updates; Incyte Corporation - Pipeline; Incyte Corporation - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 100395
Site License
USD 3000 INR 200790
Corporate User License
USD 4500 INR 301185



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]